Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-702 in Moderate to Severe Rheumatoid Arthritis (12-week Phase 2 Study)
2005-000549-13Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vx-702 in rheumatoid arthritis (RA) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: ACR20 response at Week 12. Started Apr 2005; status: completed.
02
Drugs
vx-702
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-000549-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000549-13.